2022 MIPS Measure # TBD: Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer


Percentage of patients initially diagnosed with non-muscle invasive bladder cancer and who received intravesical Bacillus-Calmette-Guerin (BCG) within 6 months of bladder cancer staging.

Initial Population

All patients initially diagnosed with T1, Tis or high grade Ta non-muscle invasive bladder cancer and a qualified encounter in the measurement period.


Equals Initial population

Denominator Exclusions

  • Immunosuppressed patients, includes HIV and immunocompromised state.
  • Immunosuppressive drug therapy.
  • Active Tuberculosis.
  • Mixed histology urothelial cell carcinoma including micropapillary, plasmacytoid, sarcomatoid, adenocarcinoma and squamous disease.
  • Patients who undergo cystectomy, chemotherapy or radiation within 6 months of Bladder Cancer Staging.


  • Intravesical Bacillus-Calmette Guerin (BCG) instillation for initial dose or series.
  • BCG is initiated within 6 months of the bladder cancer staging and during the measurement period.

Numerator Exclusions

Not Applicable

Denominator Exceptions

Unavailability of BCG